COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year ...

The MINDFuL trial is a double-blind, Phase 2 proof-of-concept study examining the potential of XPro™ to slow cognitive decline in early-stage Alzheimer’s disease (AD) by targeting neuroinflammation.

THIS APPROVAL FOLLOWS PROTOCOL VALIDATION BY THE EMA AND FDA AUTHORIZATION ...

Background Steatotic liver disease-related hepatocellular carcinoma (SLD-HCC), a rising global challenge, is characterised by ...

With few treatments available to treat Alzheimer’s disease, scientists have turned to cancer drugs as a potential means of ...

This is a valuable study on how past sensory experiences shape perception across multiple time scales. Using a behavioural task and reanalysed EEG data, the authors identify two unifying mechanisms ...

Kickstart your clinical research journey with expert mentorship. Gain hands-on guidance, industry insights, and career ...

The electronic search that informed most of the clinical questions was limited to randomized phase III clinical trials and meta-analyses. For the special circumstances and populations clinical ...

As of May 2025, 62 active clinical trials are ongoing for Fabry disease, including 25 interventional and 37 observational studies, of which 8 are patient registries. Among the trials with known ...

A new study by investigators from Europe, including the Netherlands and the United Kingdom (UK), has shed light on significant ethical, administrative, regulatory, and logistical (EARL) hurdles in ...